Assessment of cardiovascular risk Circulatory System
Conditions
Interventions
Participants are randomly allocated to one of three groups:
Group 1: Participants ingest 50 mg of curcuminoids every day for 8 weeks
Group 2: Participants ingest 200 mg of curcuminoids every day for 8
Sponsors
OmniActive Health Technologies Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged between 19 and 29 years inclusive 2. Meet the minimum recommendations for health and fitness by the American College of Sports Medicine 3. Non-smoking 4. Free from any musculoskeletal, medical or metabolic contraindications to exercise 5. Have not consumed any nutritional supplements and/or ergogenic aids for the preceding 9-week period and/or not have taken any anti-inflammatory medications for the previous month 6. Good general health as determined by a health history questionnaire 7. Female participamt must be currently taking oral contraceptive or post-menopausal (i.e. not pregnant) 8. Able to provide written and dated informed consent 9. Willing and able to comply with the protocol
Exclusion criteria
Exclusion criteria: 1. Oarticipation in another clinical trial or consumption of investigational product within the previous thirty days 2. History of alcohol and/or drug abuse in the past 6 months or intends to consume either over the course of the study 3. Reported history of chronic or presence of treated or untreated bleeding disorder, diabetes mellitus, high blood pressure (systolic BP> 140 and/or diastolic BP> 90), thyroid disease, tachyarrhythmia, heart disease, kidney disease, or liver disease 4. Currently suffers from sleep disorder and/or has a known history of (or is currently being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s), which in the opinion of the investigator, might put the subject at risk and/or confound the results of the study 5. Subject has a known allergy or sensitivity to any ingredient in the test product 6. Any medical condition or uses any medication, nutritional product, dietary supplement or program, which in the opinion of the investigator, might interfere with the conduct of the study or place the subject at risk 7. History of difficulty swallowing large pills or tablets 8. Creatine use within 9 weeks prior to screening 9. History of orthopedic injury or surgery within the last 6 months 10. Has a contraindication to exercise utilized in research design 11. Subject has self-reported an abnormal resting ECG 12. Investigator is uncertain about subject’s capability or willingness to comply with the protocol requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Flow mediated dilation is measured using ultrasound scanning at baseline and 8 weeks in all participants 2. Flow mediated dilation is measured using ultrasound scanning at baseline and 8 weeks in a subset of participants who had an FMD of 7% or lower | — |
Countries
United States of America
Outcome results
None listed